SCHEMBL21597801

SCHEMBL21597801

NC1CCc2sc(NC(=O)C3CC3)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.37
NFKB1 P19838 1/20 0.37
THPO P40225 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
USP2 O75604 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
FLT3 P36888 1/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ULK1 O75385 1/20 0.36
SMYD3 Q9H7B4 1/20 0.36
LMNA P02545 1/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603764 0.83 ALDH1A1 (0.54) TP53ALOX15ALDH1A1MAPTNPC1
SCHEMBL21597427 0.83 TBXAS1 (0.46) TP53ALOX15ALDH1A1MAPTNPC1
SCHEMBL21597854 0.80 TP53 (0.41) TP53ALOX15ALDH1A1NPC1RAB9A
SCHEMBL8291574 0.80 NPC1 (0.47) TP53ALOX15ALDH1A1MAPTNFKB1
SCHEMBL21603812 0.79 ALDH1A1 (0.41) ALDH1A1MAPTNPC1RAB9AKDM4E
Trifluoroacetic Acid SCHEMBL28611854 0.79 ABL1 (0.36) ALDH1A1
SCHEMBL21597674 0.78 TP53 (0.44) TP53ALOX15ALDH1A1MAPTHIF1A
SCHEMBL21603763 0.77 TP53 (0.39) TP53ALOX15ALDH1A1MAPTHIF1A
SCHEMBL21597595 0.76 TP53 (0.54) TP53ALOX15ALDH1A1MAPTHIF1A
SCHEMBL28609236 0.76 TP53 (0.36) TP53ALOX15ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TP53 2515/4885ALOX15 217/4885ALDH1A1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.